Tuesday, March 21, 2023 | Back issues
Courthouse News Service Courthouse News Service

Biopharma Merger

WILMINGTON, Del. - Shareholders say Inhibitex, a biopharma company, is selling itself too cheaply to Bristol-Myers Squibb, for $2.5 billion or $26 a share.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.